Global Pancreatic Cancer Market 2014-2018

Global Pancreatic Cancer Market 2014-2018

Category : Healthcare
Published On : October  2014
Pages : 97



TOLL FREE
+1-971-202-1575
------------ Or -------------
help@researchbeam.com
About Pancreatic Cancer
Pancreatic cancer is a malignant cells form in the tissues of pancreas. Based on the initiation, pancreatic cancer can be classified into exocrine pancreatic cancer and endocrine pancreatic cancer. When pancreatic cancer cells spread from the pancreas to other parts of the body, it is known as metastatic pancreatic order. The incidence and mortality rate of pancreatic cancer is higher in men than in women. SEER estimates that there were 46,420 new pancreatic cancer cases recorded in the US in 2014. It also estimated that 39,590 deaths occurred in the US in 2014 as a result of pancreatic cancer, accounting for 6.8 percent of the total cancer deaths in the US.
TechNavio's analysts forecast the Global Pancreatic Cancer market to grow at a CAGR of 10.70 percent over the period 2013-2018.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Pancreatic Cancer market for the period 2014-2018. To calculate the market size, the report considers revenue generated through the sales of various drugs administered to treat different types of pancreatic cancer. 
The report also presents the vendor landscape and a corresponding detailed analysis of the vendors in the Global Pancreatic Cancer market. In addition, it discusses the major drivers that influence the growth of the market and outlines the challenges faced by the vendors.
TechNavio's report, the Global Pancreatic Cancer market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, the APAC and EMEA regions; it also covers the Global Pancreatic Cancer market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
• Americas 
• APAC  
• EMEA
Key Vendors
• Celgene 
• Eli Lilly 
• F. Hoffmann-La Roche 
• Novartis 
• Pfizer 
Other Prominent Vendors
 
• AbGenomics International
• AB Science 
• Aduro Biotech 
• Aphios 
• Celsion
• Gilead Sciences 
• Halozyme Therapeutics 
• Merrimack Pharmaceuticals 
• Momenta Pharmaceuticals 
• OncoMed Pharmaceuticals 
• Oncozyme Pharma 
• Ostuka Holdings
• Rexahn Pharmaceuticas 
• Zeria Pharmaceutica

Market Driver
• Unmet Medical Need
• For a full, detailed list, view our report
Market Challenge
• High Recurrent Rates
• For a full, detailed list, view our report
Market Trend
• Use of Combination Therapies
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis
07. Market Segmentation by Type of Therapy
07.1.1 Chemotherapy
07.1.2 Targeted Therapy
08. Geographical Segmentation
08.1 Pancreatic Cancer Market in the US
08.2 Pancreatic Cancer market in the 5EU
09. Buying Criteria
10. Market Growth Drivers
11. Drivers and their Impact
12. Market Challenges
13. Impact of Drivers and Challenges
14. Market Trends
15. Trends and their Impact
16. Vendor Landscape
16.1 Competitive Scenario
16.1.1 Key News
16.2 Market Share Analysis 2013
16.3 Other Prominent Vendors and Future Vendors
17. Key Vendor Analysis
17.1 Celgene
17.1.1 Key Facts
17.1.2 Business Description
17.1.3 Business Strategy
17.1.4 Business Segmentation by Revenue 2011-2013
17.1.5 Sales by Geography
17.1.6 Key Developments
17.1.7 SWOT Analysis
17.2 Eli Lilly
17.2.1 Key Facts
17.2.2 Business Overview
17.2.3 Business Segmentation by Revenue 2013
17.2.4 Business Segmentation by Revenue 2012 and 2013
17.2.5 Sales by Geography
17.2.6 Business Strategy
17.2.7 Key Developments
17.2.8 SWOT Analysis
17.3 F. Hoffmann-La Roche
17.3.1 Key Facts
17.3.2 Business Overview
17.3.3 Business Segmentation by Revenue 2013
17.3.4 Business Segmentation by Revenue 2012 and 2013
17.3.5 Geographical Segmentation by Revenue 2013
17.3.6 Business Strategy
17.3.7 Recent Developments
17.3.8 SWOT Analysis
17.4 Novartis
17.4.1 Key Facts
17.4.2 Business Overview
17.4.3 Business Segmentation by Revenue 2013
17.4.4 Business Segmentation by Revenue 2012 and 2013
17.4.5 Sales by Geography
17.4.6 Business Strategy
17.4.7 Key Developments
17.4.8 SWOT Analysis
17.5 Pfizer
17.5.1 Key Facts
17.5.2 Business Description
17.5.3 Business Segmentation
17.5.4 Revenue by Business Segmentation
17.5.5 Revenue Comparison 2012 and 2013
17.5.6 Sales by Geography
17.5.7 Business Strategy
17.5.8 Key Developments
17.5.9 SWOT Analysis
18. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Pancreatic Cancer Market 2013-2018 (US$ million)
Exhibit 3: Global Pancreatic Cancer Market Segmentation by Type of Therapy
Exhibit 4: Global Pancreatic Cancer Market Segmentation by Geography 2013
Exhibit 5: Pancreatic Cancer Market in the US 2013-2018 (US$ million)
Exhibit 6: Pancreatic Cancer Market in the 5EU 2013-2018 (US$ million)
Exhibit 7: Regulatory Approval Timeline of Abraxane in the US
Exhibit 8: Regulatory Approval Timeline of Abraxane in the EU
Exhibit 9: Regulatory Approval and Revenue Trend of Abraxane
Exhibit 10: Quarterly Sales of Abraxane Segmented by Geography 2010-2014 (US$ million)
Exhibit 11: Quarterly Sales of Abraxane Segmented by Geography 2010-2014
Exhibit 12: Market Revenue of Abraxane 2010-2014 (US$ million)
Exhibit 13: Regulatory Approval Timeline of Afinitor in the US
Exhibit 14: Regulatory Approval Timeline of Afinitor in the EU
Exhibit 15: Regulatory Approval and Revenue Trend of Afinitor
Exhibit 16: Market Revenue of Afinitor 2008-2014 (US$ million)
Exhibit 17: Quarterly Sales of Afinitor 2011-2014 (US$ million)
Exhibit 18: Quarterly Sales of Afinitor Segmented by Geography 2012-2014 (US$ million)
Exhibit 19: Quarterly Sales Trend of Afinitor Segmented by Geography 2012-2014 (US$ million)
Exhibit 20: Regulatory Approval Timeline of Tarceva in the US
Exhibit 21: Regulatory Approval Timeline of Tarceva in the EU
Exhibit 22: Regulatory Approval and Revenue Trend of Tarceva
Exhibit 23: Market Revenue of Tarceva 2004-2014 (US$ million)
Exhibit 24: Quarterly Sales of Tarceva Segmented by Geography 2004-2008 (US$ million)
Exhibit 25: Quarterly Sales of Tarceva Segmented by Geography 2009-2014 (US$ million)
Exhibit 26: Regulatory Approval Timeline of Gemzar in the US
Exhibit 27: Regulatory Approval and Revenue Trend of Gemzar
Exhibit 28: Market Revenue of Gemzar 1996-2011 (US$ million)
Exhibit 29: Regulatory Approval Timeline of Sutent in the US
Exhibit 30: Regulatory Approval Timeline of Sutent in the EU
Exhibit 31: Regulatory Approval and Revenue Trend of Sutent
Exhibit 32: Market Revenue of Sutent 2007-2014 (US$ million)
Exhibit 33: Quarterly Sales of Sutent Segmented by Geography 2007-2014 (US$ million)
Exhibit 34: Quarterly Sales of Sutent in International Markets 2010-2014 (US$ million)
Exhibit 35: Celgene Corp.: Business Segmentation by Revenue 2011-2013 (US$ million)
Exhibit 36: Celgene Corp.: Sales by Geography 2013
Exhibit 37: Eli Lilly and Co.: Business Segmentation by Revenue 2013
Exhibit 38: Eli Lilly and Co.: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 39: Eli Lilly and Co.: Sales by Geography 2013
Exhibit 40: F. Hoffmann-La Roche: Business Segmentation by Revenue 2013
Exhibit 41: F. Hoffmann-La Roche: Business Segmentation by Revenue 2012 and 2013
Exhibit 42: F. Hoffmann-La Roche: Geographical Segmentation by Revenue 2013 (Pharmaceuticals Division)
Exhibit 43: F. Hoffmann-La Roche: Geographical Segmentation by Revenue 2013 (Diagnostics Division)
Exhibit 44: Novartis AG: Business Segmentation by Revenue 2013
Exhibit 45: Novartis AG: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 46: Novartis AG: Sales by Geography 2013
Exhibit 47: Pfizer Inc.: Business Segmentation
Exhibit 48: Pfizer Inc.: Revenue by Business Segmentation 2013
Exhibit 49: Pfizer Inc.: Revenue by Business Segmentation 2012 and 2013
Exhibit 50: Pfizer Inc.: Revenue by Geography 2013



Enquiry Before Buy
image
Can´t read the image ? refresh here.